Save time and money with
Med Tech Market Research


MedTech Business intelligence
supplied through Trade Tracker, Research and Markets and GlobalData

Bristol-Myers Squibb Co.: PharmaVitae Profile

Publication Date: Sept 2009
Publisher: Datamonitor
Pages: 120

Price: £5,700.00
approximately: $9,444 | €6,321

Buy now >>
(managed by Piribo)

Summary

This analysis examines the historical and forecast performance for BMS in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Scope

Highlights

Reasons to Purchase

  • Benchmark Bristol-Myers Squibb's performance against key rivals in the ethical pharmaceutical sector
  • Assess how BMS is exploring the fast-growth oncology and immunology disease markets to drive long-term sales in the face of blockbuster patent expiry
  • Investigate the strength of BMS's pipeline, its product collaborations with AstraZeneca and Pfizer and the recent acquisition of Medarex.

Buy now >>

Contents

  • ABOUT DATAMONITOR HEALTHCARE
    • About the PharmaVitae team
  • Chapter 1 About this profile
    • PharmaVitae Explorer database
  • Chapter structure
    • Executive summary
    • Quarterly news update
    • Company introduction
    • Company sales
    • Company financials
    • Key products and competitors
    • Data sourcing
    • Sales data
    • Analyst consensus
  • Chapter 2 Executive summary
    • Key findings
    • Prescription pharmaceutical sales and growth rate performance, 2002-14
    • Financial performance, 2002-14
    • Bristol-Myers Squibb: PharmaVitae forecasts at a glance
    • Strategic insight
    • Plavix exposure drives BMS over 2012 patent cliff
    • BMS has the second fastest expiry decline within Big Pharma
    • BMS will focus on areas of high unmet need to mitigate the decline of its CV portfolio
    • BMS builds Big Pharma collaborations
    • Pfizer collaboration for apixaban
    • Antidiabetic collaboration with AstraZeneca
    • BMS fast evolving into a fully-fledged biopharmaceutical player
    • Productivity transformation initiative expected to lower operating costs
    • Increasingly profitable business model makes BMS an attractive M&A target
    • SWOT analysis
    • Strengths
    • Weaknesses
    • Opportunities
    • Threats
    • Table of Contents
    • Table of figures
  • Chapter 3 Quarterly news update
    • Product developments
    • Deals and alliances
    • Company announcements
    • Future product milestones
  • Chapter 4 Company introduction
    • Key findings
    • Background
    • Key corporate developments
    • Bristol-Myers
    • Squibb
    • Bristol-Myers Squibb
    • M&A history
    • Medarex
    • Kosan Biosciences
    • Adnexus Therapeutics
    • Acordis Speciality Fibres
    • DuPont Pharmaceuticals
    • Mead Johnson
    • ConvaTec
    • Medical Imaging
    • Consumer Medicines
    • Oncology Therapeutics Network
    • Corporate restructuring to focus on pharma
  • Chapter 5 Company sales
    • Key findings
    • Prescription pharmaceutical sales and growth rate analysis, 2002-14
    • Historical analysis
    • Forecast analysis
    • Product analysis
    • Product analysis, 2002-08
    • Growth drivers
    • Growth resistors
    • Product analysis, 2008-14
    • Growth drivers
    • Growth resistors
    • Therapy area analysis
    • Geographic analysis
    • Launch/core/expiry analysis
    • Explanation of launch/core/expiry analysis
    • Launch analysis, 2008-14
    • Core analysis, 2008-14
    • Expiry analysis, 2008-14
    • Launch/core/expiry configuration, 2008-14
    • Molecule type analysis
    • Externalization analysis
  • Chapter 6 Company financials
    • Key findings
    • Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08
    • Financial statements, 2001-07
    • Operating costs and profit analysis
    • Operating costs and profit analysis, 2002-08
    • Operating cost ratio and profit margin analysis, 2002-08
    • Operating cost ratio and profit margin analysis, 2008-14
    • Operating costs and profit analysis, 2008-14
  • Chapter 7 Key products and competitors
    • Key findings
    • Overview
    • Infectious diseases
    • Reyataz
    • Overview
    • Sales forecast
    • Kaletra set precedent for all future protease inhibitors
    • Reyataz overtakes Kaletra as the new class leading protease inhibitor
    • Competition intensifies following arrival of Prezista
    • Sustiva franchise
    • Overview
    • Sales forecast
    • Sustiva sales lifted by bulk use in market-leading Atripla
    • Atripla's dominance threatened by drugs offering better tolerability
    • Sustiva patent expiry to shift market share back to Truvada
    • Baraclude
    • Overview
    • Sales forecast
    • A single product hepatitis B franchise
    • Oncology
    • Erbitux
    • Overview
    • Sales forecast
    • Lucrative oncology license for North American market
    • Additional approvals key to expanded market potential
    • Sprycel
    • Overview
    • Sales forecast
    • Further approvals will help to reinforce market position
    • BMS pursues indication expansion in order to grow Sprycel commercial potential
    • Ixempra
    • Overview
    • Sales forecast
    • Central nervous system
    • Abilify
    • Overview
    • Sales forecast
    • Extended Abilify co-promotion terms reinforces BMS's position in psychiatric market
    • Extension to Abilify co-promotion agreement reinforces BMS's position in psychiatric market
    • Intramuscular version of Abilify is unlikely to challenge Zyprexa IM
    • Potential market-leading oral antipsychotic after genericization of class
    • Immunology & inflammation
    • Orencia
    • Overview
    • Sales forecast
    • Uptake of novel autoimmune disorder biologic increases with experience and confidence
    • Cardiovascular
    • Plavix
    • Overview
    • Sales forecast
    • Market-leading antithrombotic
    • Patent protection secured out to 2011
    • Endocrine, metabolic & genetic disorders
    • Onglyza
    • Overview
    • Sales forecast
  • Chapter 8 Appendix
    • R&D pipeline
    • References
    • Datamonitor reports
    • Abbreviations
    • Exchange rates
    • About Datamonitor
    • About Datamonitor Healthcare
    • Datamonitor consulting
    • Disclaimer
  • List of Tables
    • Table 1: Bristol-Myers Squibb - PharmaVitae forecasts at a glance
    • Table 2: Bristol-Myers Squibb's exposure to Plavix sales ($m), 2008-14
    • Table 3: Expiry sales across Big Pharma ($m), 2008 & 2014
    • Table 4: Key Brands within Bristol-Myers Squibb's prescription portfolio
    • Table 5: Bristol-Myers Squibb key product developments, 2009
    • Table 6: Bristol-Myers Squibb deals and alliances, 2009
    • Table 7: Bristol-Myers Squibb company announcements, 2009
    • Table 8: BMS future product milestones, 2009-11
    • Table 9: Bristol-Myers Squibb product portfolio overview ($m), 2002-08
    • Table 10: Bristol-Myers Squibb product portfolio overview ($m), 2008-14
    • Table 11: Bristol-Myers Squibb prescription pharmaceutical sales by therapy area ($m), 2008-14
    • Table 12: Bristol-Myers Squibb prescription pharmaceutical sales by geographic region ($m), 2008-14
    • Table 13: Bristol-Myers Squibb launch portfolio overview ($m), 2008-14
    • Table 14: Bristol-Myers Squibb core portfolio overview ($m), 2008-14
    • Table 15: Bristol-Myers Squibb expiry portfolio overview ($m), 2008-14
    • Table 16: Bristol-Myers Squibb prescription pharmaceutical sales by molecule type ($m), 2008-14
    • Table 17: Bristol-Myers Squibb prescription pharmaceutical sales by source ($m), 2008-14
    • Table 18: Total Bristol-Myers Squibb sales by business unit ($m), 2002-08
    • Table 19: Bristol-Myers Squibb operating revenue/cost analysis ($m), 2002-08
    • Table 20: Bristol-Myers Squibb operating cost ratio analysis (% of total revenues), 2002-08
    • Table 21: Bristol-Myers Squibb operating cost ratio analysis (% of total revenues), 2008-14
    • Table 22: Bristol-Myers Squibb operating revenue/cost analysis ($m), 2008-14
    • Table 23: Key products overview
    • Table 24: Reyataz: overview
    • Table 25: Reyataz: sales forecast ($m), 2008-14
    • Table 26: Sustiva franchise: overview
    • Table 27: Sustiva franchise: sales forecast ($m), 2008-14
    • Table 28: Baraclude: overview
    • Table 29: Baraclude: sales forecast ($m), 2008-14
    • Table 30: Erbitux: overview
    • Table 31: Erbitux: sales forecast ($m), 2008-14
    • Table 32: Sprycel: overview
    • Table 33: Sprycel: sales forecast ($m), 2008-14
    • Table 34: Ixempra: overview
    • Table 35: Ixempra: sales forecast ($m), 2008-14
    • Table 36: Abilify: overview
    • Table 37: Abilify: sales forecast ($m), 2008-14
    • Table 38: Orencia: overview
    • Table 39: Orencia: sales forecast ($m), 2008-14
    • Table 40: Plavix: overview
    • Table 41: Plavix: sales forecast ($m), 2008-14
    • Table 42: Onglyza: overview
    • Table 43: Onglyza: sales forecast ($m), 2008-14
    • Table 44: Bristol-Myers Squibb's R&D pipeline (Phase I-registration)
    • Table 45: Exchange rates, 2009
  • List of Figures
    • Figure 1: The PharmaVitae Explorer
    • Figure 2: Bristol-Myers Squibb prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14
    • Figure 3: Bristol-Myers Squibb's financial performance ($m), 2002-14
    • Figure 4: Bristol-Myers Squibb's exposure to Plavix ($m), 2002-14
    • Figure 5: Bristol-Myers Squibb's therapeutic focus, 2002-14
    • Figure 6: Bristol-Myers Squibb SWOT analysis
    • Figure 7: Bristol-Myers Squibb prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14
    • Figure 8: Key product sales ($m), 2002-14
    • Figure 9: Bristol-Myers Squibb key sales growth drivers and resistors ($m), 2002-08
    • Figure 10: Bristol-Myers Squibb key sales growth drivers and resistors ($m), 2008-14
    • Figure 11: Bristol-Myers Squibb prescription pharmaceutical sales by therapy area ($m), 2002-14
    • Figure 12: Bristol-Myers Squibb prescription pharmaceutical sales by geographic region ($m), 2002-14
    • Figure 13: Bristol-Myers Squibb launch/core/expiry configuration ($m), 2008-14
    • Figure 14: Bristol-Myers Squibb prescription pharmaceutical sales by molecule type ($m), 2002-14
    • Figure 15: Bristol-Myers Squibb prescription pharmaceutical sales by source ($m), 2002-14
    • Figure 16: Bristol-Myers Squibb operating revenue/cost analysis ($m), 2002-14

Buy now >>

 

To top